"Gemfibrozil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
| Descriptor ID |
D015248
|
| MeSH Number(s) |
D02.241.081.114.968.500.750 D02.241.081.944.509.350 D02.355.726.305.750 D02.455.426.559.389.657.654.305.750 D10.251.400.895.593.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gemfibrozil".
Below are MeSH descriptors whose meaning is more specific than "Gemfibrozil".
This graph shows the total number of publications written about "Gemfibrozil" by people in this website by year, and whether "Gemfibrozil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gemfibrozil" by people in Profiles.
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
-
Gemfibrozil inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl coenzyme A reductases and blocks intracellular growth of these bacteria in macrophages. J Bacteriol. 2009 Aug; 191(16):5262-71.
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
-
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol. 2005 Jan 15; 95(2):189-93.
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
-
Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003 Oct 27; 163(19):2394-5.
-
Combination lipid-lowering therapy in diabetes. Curr Diab Rep. 2003 Jun; 3(3):263-8.
-
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins. Curr Atheroscler Rep. 2000 Jan; 2(1):11-3.
-
Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: studies before and after triglyceride-lowering therapy. Metabolism. 1998 Feb; 47(2):234-42.
-
Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group. Clin Ther. 1995 Mar-Apr; 17(2):186-203.